Rising interest rates and fears of a recession have caused a great deal of uncertainty over the past 12 months. This explains why the Nasdaq Composite has dipped 13% during that time.

But there are plenty of growth-oriented companies whose stocks have outperformed the market amid this volatility -- for example, the genomic test maker Veracyte (NASDAQ: VCYT) has lost just 9% of its value in the last year.

But should growth investors buy the stock at this time? Let's dig into Veracyte's fundamentals and valuation to get an answer to that question.

Continue reading

Source Fool.com